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Abstract
Plasmalemma vesicle associated protein (Plvap) is an endothelial protein with roles in endothelial
diaphragm formation and maintenance of basal vascular permeability. At the same time Plvap has
roles in immunity by facilitating leukocyte diapedesis at inflammatory sites and controlling
peripheral lymph node morphogenesis and the entry of soluble antigens into lymph node conduits.
Based on its postulated role in diapedesis, we have investigated the role of Plvap in hematopoiesis
and show that deletion of Plvap results in a dramatic decrease of IgM+IgDlo B cells in both the
spleen and peritoneal cavity. Tissue specific deletion of Plvap demonstrates that the defect is B
cell extrinsic, as B cell and pan hematopoietic Plvap deletion has no effect on IgM+IgDlo B cell
numbers. Endothelial specific deletion of Plvap in the embryo or at adult stage recapitulates the
full Plvap knockout phenotype whereas endothelial specific reconstitution of Plvap under the
Chd5 promoter rescues the IgM+IgDlo B cell phenotype. Taken together, these results show that
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Plvap expression in endothelial cells is important in the maintenance of IgM+ B cells in the spleen
and peritoneal cavity.
Introduction
The innate immune response is the host’s first and most rapid response to infection with a
pathogen, whereas the adaptive immune response involves a complex process including
activation, expansion and differentiation of pathogen-specific B and T cells. The
development of adaptive immunity requires several days to weeks to generate a long-
standing effector and memory immune response (1, 2). A key transition from innate to
adaptive immunity is mediated by the marginal zone (MZ) B and B-1 cells as they produce
the first set of low-affinity antibodies against the pathogen (3). MZ B and B-1 cells are
localized in marginal sinus and peritoneal cavity, respectively, where they are favored as the
first cells to sample antigens in the blood and gut. Moreover, MZ and B-1 B cells are well
characterized as having a low activation threshold and their BCRs recognize a wide range of
microbial antigens (4). Both B cell subsets significantly contribute to levels of serum IgM,
and the production of natural antibodies. Natural antibodies in many cases can be specific to
pathogen-encoded molecules and be critical in the rapid neutralization of both viruses and
bacteria (5).
MZ B cells arise from bone marrow precursors through transitional B cells, which colonize
the periarteriolar lymphoid sheath (5). The differentiation of transitional B cells to MZ B
cells is driven by a weak BCR activity through a dependent pathway Bruton’s tyrosine
kinase (6–8). This and the interaction of NOTCH expressed on transitional B cells with the
ligand, Delta-like 1, on endothelial cells induce the differentiation to MZ B cells (9). The
homing of MZ B cells is dependent on circulating sphingosine-1- phosphate (S1P) binding
to S1P1 and S1P3 receptors expressed in the endothelial cells of blood vessels of MZ (10,
11). After migration, MZ B cells are retained by the interaction of αLβ2 and α4β1 with
ICAM1 and VCAM1, respectively (12).
In contrast, B-1 cells are competently produced before birth and throughout the first couple
weeks after birth. The precursors for B-1 cells have been discovered in the splanchnopleura
region, yolk sac and intra-embryonic hemogenic endothelium, fetal liver but they are absent
from adult bone marrow (13–16). B-1 cells constantly circulate to and from the peritoneal
space across the omentum in a process that involves CXCL13, which is likely produced by
macrophages (17). Collectively, these findings show that B cell progenitors migration is
highly regulated by molecules expressed on endothelial cells. However, it is not known
whether molecules expressed on endothelial cells are involved in B cell differentiation and
trafficking.
Plasmalemma vesicle associated protein (Plvap) is a vertebrate gene (18, 19) whose product,
Plvap, is a heparin-binding (20) homodimeric, single span type II membrane glycoprotein
(21–23) critical for the formation of the stomatal diaphragms of caveolae, transendothelial
channels and vesiculo-vacuolar organelles as well as the diaphragms of fenestrae in both
mice (24–27) and humans (28). Microscopic (19, 22) and genetic (26, 28, 29) lines of
investigation led to the conclusion that Plvap is specifically expressed in the endothelial
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cells of blood vessel capillaries and venules in select vascular beds and in the heart
endocardium and absent from lymphatic endothelial cells. This pattern of expression was
fully supported by a large body of literature obtained with two endothelial specific
monoclonal antibodies that bind Plvap, such as MECA-32 (30, 31) in the mouse and PAL-E
(32–34) in humans (reviewed in (35, 36)). However, recently Plvap expression was also
demonstrated in the sinus lymphatic endothelial cells of peripheral lymph nodes (PLN)
while confirming its absence from peripheral lymphatics elsewhere ((27) and immgen.org).
At the whole organism level, endothelial diaphragms formed by Plvap (24, 37, 38) are
critical for maintaining basal permeability of fenestrated blood vessels, their absence
resulting in disrupted blood homeostasis and reduced survival (26, 28). In PLN, Plvap
positive diaphragms in the sinus lymphatic endothelial cells control the entry of soluble
antigens and lymphocytes in PLN parenchyma (27).
The expression of Plvap and diaphragm formation is increased in activated endothelial states
associated with inflammation (39, 40) and physiological and pathological angiogenesis (35,
41, 42) where it has active roles. Plvap is required for cancer progression (43) and
diapedesis of leukocytes into inflammation sites in vivo (31). In vitro Plvap knock-down and
antibody-mediated blockade experiments, suggest that endothelial Plvap is important for the
transcellular transmigration but not for adhesion and rolling of lymphoblasts with no effect
on neutrophils transmigration (31). Plvap is thought to control the transcellular migration of
lymph-borne lymphocytes into PLN parenchyma (27). Deletion of Plvap results in defective
PLN morphogenesis with mild decreases in the T cell compartment (both CD4 and CD8 T
cells), hyperplastic B cell follicles and increases in both PLN B and T cells activation.
Intriguingly, Plvap deletion increases the entry of adoptively transferred lymph borne
splenocytes (both B and T cells) whereas its ligation with MECA-32 antibody inhibits the
recruitment of these subsets (27). The mechanism of how Plvap mediates transendothelial
migration of immune cells in currently unclear.
Here, we have examined whether Plvap plays a role in the development and homeostasis of
hematopoietic lineages taking advantage of recently created genetic models of Plvap gain
and loss of function and endothelial specific reconstitution (26). Our studies show that
deletion of Plvap results in an intense reduction of IgM+ B cells in both spleen and
peritoneal cavity. Tissue specific deletion of Plvap demonstrates that the defect is B cell
extrinsic, as B cell and pan hematopoietic Plvap deletion has no effect on IgM+ B cell
numbers. Endothelial specific deletion of Plvap recapitulates full Plvap knockout, while
endothelial specific reconstitution of Plvap rescues the IgM+ B cell phenotype. Taken
together these results demonstrate that Plvap expression on endothelial cells is key in the
maintenance of IgM+ B cells into spleen and peritoneal cavity.
Material and Methods
Conditional deletion of Plvap
Homozygous PlvaploxP (PlvapL/L) mice were generated by knock-in using homologuous
recombination in mice, as already described (26). PlvapL/L mice express Plvap at normal
levels and have no overt phenotype (26). The PlvapL/L mice were bred to mice expressing
the cre recombinase under the control of different promoters allowing to generate compound
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mice where Plvap was deleted in: a) germline (label Plvap−/−, genotype Plvap−/−;CMV-
cretg/+) using CMV-cretg/+ transgenic mice, (JAX strain BALB/c-Tg(CMV-cre)1Cgn/J). b)
endothelial and hematopoietic cells in the embryo using Ins-VEC-cre transgenic mice (44)
(label PlvapECKO-VEC, genotype PlvapL/L;Ins-VEC-cretg/+) c) endothelial and hematopoietic
cells in the embryo using Tie2/Tek-cretg/+ mice (JAX strain B6.Cg-Tg(Tek-cre)12Flv/J)
(label PlvapECKO-Tie2, genotype PlvapL/L;Tek-cretg/+) d) B cell specific deletion of Plvap in
the embryo using CD19-creKI/+ knock-in mice, (JAX strain B6.Cg-Cd19tm1(cre)Cgn/J) (45)
(label CD19CrexPlvapL/L, genotype PlvapL/L;CD19-creki/+) e) hematopoietic cells in the
embryo using Vav1-cre+/− transgenic mice (46), for deletion of Plvap in all the
hematopoietic cell lineages but not in endothelium (44, 46); f) for inducible deletion of
Plvap in the endothelial cells of the adult mice we used end-SCL-Cre-ERTtg/+ transgenic
mice to generate mice with the genotype: PlvapL/L; end-SCL-CreERT tg/+ (label
PlvapiECKO). Deletion of Plvap was achieved by dosing 4 weeks old mice (both males and
females) by gavage with 7 doses of 4mg tamoxifen spaced at 48 hours. Experiments were
carried out two weeks after the last tamoxifen dose administration. Control animals for
germline deletion were sex and age matched WT or CMV-cretg/+ (labeled WT) and Plvap+/−
or Plvap+/−;CMV-cretg/+ (labeled Plvap+/−) littermates. Control animals for tissue specific
deletions were sex and age matched WT or PlvapL/L littermates.
VEC-Plvap-HAtg/+ transgenic mice (26) that express Plvap-HA fusion protein specifically in
the endothelial cells under the control of cadherin 5 (VE Cadherin) promoter, were used to
reconstitute Plvap in endothelial cells in the context of the Plvap−/− (label PV1ECRC) as
described (26). The same strategy was used to reconstitute Plvap in the context of
PlvapiECKO (label PlvapiECRC, genotype PlvapL/L; end-SCL-CreERT tg/+; VEC-Plvap-
HAtg/+).
All animals were maintained in a pathogen-free facility at Dartmouth College. All
procedures were approved by the local IACUC.
Antibodies, Staining and analysis by flow cytometry
The following antibodies and staining reagents were used: IgG1 (clone A85-1), IgG2a/b
(clone R2-40), CD138 (clone 281-2), IgM (clone 11–41), CD24 (clone M1/69), CD4 (clone
RM4-5), CD21/35 (clone 7E9), CD8 (clone 53-6.7), CD25 (clone 3C7), CD62L (clone
MEL-14), CD69 (clone H1.2F3), CD44 (clone lM7), CD11c (clone HL3), CD80 (clone
16-10A1), CD86 (clone GL1), CD11b (clone M1/70), c-Kit (CD117, clone 2B8),
streptavidin-PerCP, from BD Pharmingen; Plvap (clone MECA-32) was from Abcam; CD38
(clone 90), B220 (clone 6B2), CD23 (clone B3B4), and IgD (clone 11-26c), FceRI (clone
MAR-1) from eBioscience; peanut agglutinin from Vector Laboratories. MECA-32 mAb
(anti mouse Plvap rat IgG2a) secreting hybridoma was obtained from the Developmental
Studies Hybridoma Bank (DSHB, U. Iowa) was produced in serum free conditions by
BioXCell (Lebanon, NH). The antibody was labeled with AlexaFluor (AF) fluorochromes
using the protein labeling kits for AF488, and AF647 (Invitrogen), as per manufacturer’s
instructions. Flow cytometry was performed on either a refurbished FACSCAN or a
FACSCalibur running CellQuest software (BD), or a FACSCanto running FACSDiva
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software within the Norris Cotton Cancer Center DartLab Immune Monitoring Facility. The
data analysis performed using FlowJo (Tree Star, Inc.).
Isolation of cells from spleen, peripheral lymph nodes and Peyer’s patches
To analyze B, T cells and monocytes, single-cell suspensions of lymphocytes were prepared
from spleens by mechanical disruption in HBSS followed by passing the cells through a
70μm cell strainer. In experiments where dendritic cells were profiled an enzymatic
digestion step (45min, 37°C) was included using DNAse (10 mg/mL Roche) and Liberase
(12.5 mg/mL, Roche) before mechanical disruption. Cells were collected by centrifugation
(5min, 500xg, 4°C) and red blood cells were lysed (2min, 37°C) using RBC Lysis buffer
(BioLegend). Total number of cells and cell viability were determined using either a
hemacytometer and trypan blue or a Guava system (Millipore). Cells (105–106) were stained
with antibody cocktails, as noted. Analysis was performed after co-staining with the cocktail
of antibodies by flow-cytometry. For isolation of peritoneal cells, the peritoneal cavity was
flushed with 5 mL warm (37°C) PBS, 2% BSA, 2mM EDTA, 0.02% sodium azide and 10
U/mL Heparin.
Analysis of Plvap expression in splenocytes of naïve and LPS treated mice
Female wild type C57Bl6/J mice were either treated with 50 μg of LPS (E. coli 055:B5,
Sigma) in PBS or an equal volume of PBS alone (control mice), i.p. 12 hrs before spleens
were harvested, enzymatically dissociated, as noted above, followed by antibody staining of
splenocytes, and analyzed by flow cytometry.
Immunofluorescence and Laser Confocal microscopy
Tissues were snap-frozen in optimal cutting temperature medium and sectioned to 8 μm.
Sections were collected on charged slides (Surgipath) fixed (−20°C, 10min) with cold
methanol, rinsed (3×2min, RT) in PBS, encircled with hydrophobic barriers (PapPen),
blocked (30min, RT) with 10% rat serum in PBS containing 10μg/ml mouse Fc block,
incubated (1h, RT, in dark) with various fluorescently labeled primary antibody cocktails in
blocking buffer, rinsed (3×5min, RT, in dark) again in PBS, stained (10min, RT, in dark)
with 300 nM 40,6-diamidino-2-phenylindole dihydrochloride (DAPI, D1306; Life
Technologies) and washed (3× 5 min, RT) in PBS. Labeled sections were mounted under
#1.5 coverslips using a polymerizing mounting medium (Fluoromount G, Southern Biotech).
The antibodies used were: rat anti-mouse Plvap– AF568 (clone MECA-32), rat anti-mouse
CD169 -FITC (clone MOMA-1, AbD Serotec) and rat anti-mouse/human B220-AF647
(clone 6B2). Labeled sections were analyzed using a Zeiss LSM510 Meta confocal
microscope equipped with appropriate lasers (405 nm, 488 nm, 532nm, 633nm) and filters,
all within the Norris Cotton Cancer Center microscopy facility. The acquired images were
processed for brightness and contrast and analyzed using ImageJ (http://imagej.nih.gov/ij/),
and the figures were mounted using Adobe Photoshop and Adobe Illustrator CS6.
Statistics
Results are expressed as mean plus or minus SEM. Two-tailed Student t test with unequal
variance was used to evaluate the statistical significance of the data.
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Results
Deletion of Plvap in mice results in reduced numbers of splenic IgM+ B cells
Plvap is an endothelial protein that is involved in the diapedesis of leukocytes at sites of
inflammatory challenge and PLN sinuses. Diapedesis is a process that is central to the
development and homeostasis of hematopoietic lineages. To understand the role of Plvap in
these processes, we used recently generated Plvap−/− mice (26) to characterize the function
of this molecule on the numbers and subset composition of leukocytes in the blood, spleen,
PLN and Peyer’s patches (PP). Plvap−/−, Plvap+/− and wild type (WT) littermate control
mice were profiled by flow cytometry to determine whether there are modifications in terms
of leukocyte subset numbers, frequency or function. No differences were found in cellular
composition of peripheral blood, LN and PP with respect with percentages, number and
viability of granulocytes, T- and B-lymphocytes, NK cells and monocytes (Fig. 1A,
supplemental Fig. S1 and data no shown). In the spleen, there was a drastic reduction in the
percentage and absolute number of IgM+ IgD− B cells in Plvap−/− mice (Fig. 1B and 1C),
whereas IgD+ B cells were not affected (Fig. 1B).
In the spleen, there are several prominent B cell subsets that are represented (47). To
evaluate whether the reduction of this population is due to a reduction of a specific sub-
population of splenic B cells, we stained with a panel of antibodies that identify those
subpopulations (47). Neither the percentage of follicular (CD21/35int IgMint) or marginal
zone B cells (CD21/35+ IgM+) is affected in Plvap−/− mice (Fig. 1D). Interestingly,
CD21/35lo IgM+ B cells are reduced in the Plvap−/− mice compared with the WT or Plvap+/−
mice (Fig. 1D and E). Lastly, CD21/35lo IgM+ B cells can be subdivided in Transitional 1
(T1) or Transitional 2 (T1) B-lymphocytes using the expression of CD23 and HSA (Figure
1F). Our results show that the proportion of T1 or T2 B cells is not affected in the Plvap−/−
mice (Figure 1F and G), indicating that both, T1 and T2 B cells are reduced. Taken together,
these results show that amongst the splenic B cell populations, in Plvap-deficient mice there
is a selective reduction in tansitional IgM+ B cells.
Similarly, no difference in the proportion of transitional B cells in Plvap−/− mice (data not
shown) was found when expression of CD93 was used for the analysis of transitional B cells
(48). Thus, irrespective of the markers used to analyze transitional B cells, we obtain the
same results.
IgM+ B cells are reduced in the peritoneum of Plvap−/− mice
Based on the above observations showing a decrease of IgM+ B cells in the spleen of
Plvap−/− mice, we hypothesized that the same reduction would also be found in peritoneal
B-1 B cells. Profiling of the resident leukocytes in the peritoneum obtained by peritoneal
lavage, demonstrated a drastic reduction in the total number of cells in the peritoneum of
Plvap−/− mice compared to WT or Plvap+/− littermates (Fig. 2A). The reduction in total
viable leukocyte numbers in the peritoneal cavity was accompanied by a low percentage and
absolute number of IgD+ B cells and the absence of IgM+ IgDlow B cells (Fig. 2B–D).
Taken together these results suggest that Plvap plays a role in the recruitment or retention of
B cells into the peritoneal cavity and/or their survival.
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Due to the drastic reduction of cells in the peritoneum cavity of Plvap−/− mice, we also
analyzed the percentage of mast cells and monocytes in this compartment. Our results show
that mast cells (cKit+ FceRI+ cells, supplemental Fig. S2A) and monocyte (CD11b+ Gr-1+
cells, data not shown) percentages were also reduced in Plvap−/− mice compare with control
mice, indicating that Plvap is an important molecule in migration to, or retention into the
peritoneum.
Plvap deletion within the hematopoietic compartment does not impact on the frequency of
B cells in the spleen and peritoneum
To understand the underlying mechanisms responsible for altered B cell frequencies in the
spleen and peritoneum, we sought to determine whether these effects are B cell intrinsic or
extrinsic. First, we inquired whether Plvap was expressed on hematopoietic cells and,
second, established the impact on B cell frequencies of genetic B-cell specific and pan-
hematopoietic deletion of Plvap.
LPS-activated or resting B cells or dendritic cells did not express Plvap, as detected with
antibody staining and using Plvap−/− splenocytes as controls. Furthermore, CD4+ and CD8+
T cells were also negative for Plvap expression (Fig. 3A, B and C). Examination of Plvap
expression by confocal microscopy revealed that expression was limited to the splenic blood
vessels in the MZ area (determined by MOMA-1+ macrophage localization) (Figure 3D).
Taken together, these data suggest that Plvap is not expressed within the hematopoietic
subsets studied, in agreement with recent data published by the Immunological Genetic
Consortium (immgen.org) (49).
While expression analysis conclusively established the lack of hematopoietic expression of
Plvap, genetic deletion of Plvap in hematopoietic cells and subsets was used to confirm
these findings. PlvapL/L mice were interbred with CD19-Cre (45) or Vav1-Cre mice (46) to
obtain compound mice lacking Plvap in the B cells (CD19CrexPlvapL/L) or all hematopoietic
cells (VavCrexPlvapL/L) (26), respectively. VavCrexPlvapL/L mice have over 97% Plvap
deletion in the hematopoietic compartment (26). B cells isolated from CD19CrexPlvapL/L
mice using magnetic separation showed >95% deletion of Plvap (data not shown). Immune
profiling of the peritoneal lavage showed that there was no effect on B frequencies or
phenotype in the spleen and peritoneum in either CD19CrexPlvapL/L (Fig. 4A – B) or
Vav1CrexPlvapL/L (Fig. 4C–D) mice. The combination of microscopy, flow cytometry, and
genetic data clearly demonstrate that Plvap is not expressed in the hematopoietic
compartment and that the maintenance of IgM+ B cells in both spleen and peritoneal cavity
is due to Plvap expression outside the hematopoietic compartment.
Plvap deletion on endothelial cells reduces IgM+ B cells in spleen and peritoneum
Plvap is a molecule specifically expressed in endothelial cells of blood vessels (26, 29) and
PLN sinus (27), suggesting that endothelial cells might impact on the presence of IgM+ B
cells in spleen and peritoneum. For this purpose, we made use of Tie2CrexPlvapL/L mice
(26) where Plvap is efficiently (>95%) deleted in the endothelial cells and the hematopoietic
compartment at embryonic stage. The results obtained in Tie2CrexPlvapL/L mice
phenocopied those obtained in Plvap−/− mice. There was a reduction in IgM+ IgD− B cell
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percentage in the spleen from Tie2CrexPlvapL/L compared with control littermates (Fig. 5A–
C). Additionally, there also was a striking reduction in the percentage of IgD+ and IgMpos
IgD− B cells in the peritoneal cavity of Tie2CrexPlvapL/L compared to control mice (Figure
5D–F). These data suggest that the expression of Plvap on endothelial cells regulates the
numbers of IgM+ B cells in the spleen and peritoneal cavity.
Endothelial reconstitution of Plvap rescues the Plvap−/− phenotype and restores B cell
frequencies in the spleen and peritoneal cavity
In order to demonstrate that Plvap−/− phenotype is not due to a distortion of other genetic
loci close to the Plvap locus, we transgenically complemented the Plvap-deficiency by the
expression of Plvap-HA in endothelial cells of Plvap−/− mice (26). Previously, we have
generated mouse lines (VEC-Plvap-HA+/tg) ta (26) expressing Plvap under the control of the
VE Cadherin promoter and 5′ intronic enhancer (50). We used VEC-PlvapHA+/tg and
Plvap+/− mice, to generate compound Plvap−/−; VEC-PlvapHA+/tg (PlvapECRC) mice, which
display between 30% and 50% reconstitution of native endothelial Plvap levels (26).
As shown in Fig. 6, IgM+ IgDlow B cells are recovered to normal levels in both spleen (Fig.
6A–C) and peritoneum (Fig. 6D–F) of PlvapECRC mice compare to Plvap−/− mice.
Moreover, IgD+ B cells were also recovered in the peritoneum of PlvapECRC mice (Fig. 6D–
F). Together all these results suggest that the expression of Plvap in endothelial cells is
necessary to maintain normal levels of B cells in the spleen and peritoneum compartment.
Plvap deletion in blood vessel endothelial cells does not affect the development of B cells
in the bone marrow
To determine whether Plvap deletion leads to a defect in B cell development in bone
marrow, we profiled B cells progenitors in the marrow of PlvapL/L; end-SCL-CreERT tg/+
compound mice (PlvapiECKO) and mice with endothelial reconstitution of Plvap in the
context of the PlvapiECKO (labeled PlvapiECRC mice) (see Methods). The promoter driving
the expression of CreERT fusion protein consists of SV40 virus minimal promoter and the
endothelial enhancer of the Stem Cell Leukemia gene (SCL) (51). This compound promoter
confers activity in endothelial cells from select vascular beds, bone marrow included, as
previously shown (51, 52). To minimize the effects on the peritoneal cavity the tamoxifen
was administered by gavage.
As shown in Fig. 7A and 7B, IgM+ IgDlow B cells are reduced in both spleen (Fig. 7A–B)
and peritoneum (Fig. 7C–D) of PlvapiECKO mice compared to control (tamoxifen treated
PlvapL/L) mice, whereas endothelial reconstitution in PlvapiECRC mice reverses the effect. In
addition, IgD+ B cells were also reduced in the peritoneum of PlvapiECKO mice (Fig. 7C–D),
indicating that endothelial deletion in adult mice has a similar phenotype as that obtained in
Plvap−/− mice with respect to B-1 and MZ B cells. (Fig. 1).
Using these models, we analyzed the proportion of immature B cells (B220+IgMhiIgD+),
mature B cells (B220+IgMintIgD+) and pre-B cells (B220+IgM+IgD+) from bone marrow
(53, 54). However, no changes were detected in B cell subsets in the bone marrow of
PlvapiECKO mice as compared to controls or PlvapiECRC mice (Fig. 7E–G). These results
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together suggest that the defect observed in the splenic immature B cells and peritoneum B
cells are not due to a defect in the B cell development in the bone marrow.
Discussion
The development of effective immune responses is dependent on endothelial cell-mediated
leukocyte migration into sites of inflammation. The results presented here are the first to
determine the critical role of Plvap in the maintenance of IgM+ B cells in spleen and
peritoneum. We show that the lack of Plvap results in a reduction of transitional splenic
IgM+ B cells as well as B-1 B cells in the peritoneum. The tissue specific deletion of Plvap
clearly demonstrate that the role of Plvap is extrinsic to the B cell compartment, as B cell
and pan hematopoietic Plvap deletion has no effect on the IgM+ B cells frequencies in either
the spleen or peritoneal cavity. In contrast, endothelial specific deletion of Plvap
recapitulates full Plvap knockout phenotype and endothelial specific reconstitution of Plvap
in the context of germline Plvap knockout rescues the IgM+ B cell phenotype. Taken
together, these results conclusively demonstrate that Plvap expression in endothelial cells is
key in maintenance of IgM+ B cells in spleen and peritoneal cavity. The reduced number of
immature B cells in spleen and B-1 cells in the peritoneum of Plvap deficient mice could
also explain the previously reported marked reduction of IgM and IgA titers in Plvap
deficient mice (26), further suggesting that Plvap may regulate the abundance of B cells that
produce natural antibodies.
Previous reports have shown Plvap expression in spleen ((19, 55) and immgen.org),
especially on the endothelial cells of the marginal sinus of the spleen (55). Our observations
confirm these findings by showing Plvap expression on vessels in the marginal zone of
spleen (identified by co-localization of MOMA-1+ macrophages) as well as capillaries in
the red pulp. Thus Plvap is expressed at the site where it could regulate IgM+ B cells
trafficking or retention in this histological site. While human Plvap expression has been
reported in circulating human lymphocytes and monocytes (i.e. PBMCs) by intracellular
staining (31), we could not find Plvap expression by antibody staining in a variety of
circulating or parenchymal murine immune subsets. Our data is in accordance with RNAseq
data on Plvap expression, published by immgen.org (49, 56). Additionally, we found that
neither B cells nor dendritic cells express Plvap in basal or under inflammatory (LPS
stimulation) conditions. Furthermore, when we abrogate Plvap expression on B cells or in
the hematopoietic compartment, there is no effect on the abundance of IgM+ B cells in the
spleen or peritoneum. These findings suggest that if Plvap has a B cell trafficking/retention
function in the spleen or peritoneum, this role is not B cell or hematopoietic cell intrinsic. In
contrast, when we used a mouse model where the lack of Plvap was specific to endothelial
cells, the defect in B cell migration/retention was indistinguishable from that observed in the
global Plvap deficient mice. Furthermore, the transgenic overexpression of Plvap expression
on endothelial cells in Plvap deficient mice rescued the phenotype. Together, these results
demonstrate that Plvap expression in endothelial cells is key in the B cell trafficking/
retention in the spleen and peritoneum.
Considering the data in the literature, there are several mechanisms by which Plvap may
lower the number of B-1 and MZ B cells:
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a. Plvap might hamper the generation of the B-1 B cell hematopoietic
progenitors in the vascular plexus of the amniotic sac and hemogenic
endothelium (16, 57, 58) where Plvap is expressed very early (18, 59).
Preliminary data show that the number of B-1 B cell progenitors in the
amniotic sac (Yoshimoto, Yoder, Stan unpublished) at E9 in the WT,
PlvapL/L and Plvap−/− is similar. In addition, B cells precursors in the
bone marrow are also similar in the Plvap deficient mice (Figure 7), which
makes Plvap involvement in B cell development unlikely.
b. Plvap controls B-1 and MZ B cell recruitment and/or retention in the
peritoneum and spleen, respectively. Integrins, chemokines and other
adhesion molecules have been shown to be involved in B cell migration
(12, 60–62). Different types of adhesion molecules regulate distinct events
in lymphocyte extravasation. We know from these studies that integrins
play a role in leukocyte tethering, whereas chemokines play a role in the
rolling process (63). Immature B cells express αLβ2 and α4β1, which
retain B cells in the splenic marginal sinus, where they interact with their
ligand, ICAM1 and VCAM1 expressed in endothelial cells (12). In
addition, an increased gradient of CXCL13 in the periarterial lymphocyte
sheath induces the migration of B cells from marginal zone to the follicles
(64). In contrast, S1P1 expressed on B cells is able to induce the migration
of B cells to the sinus of marginal zone and peritoneum (10, 11, 65).
Conceivably S1P1 expressed on B cells could interact with Plvap, through
vim, to permit the extravasation of B cell progenitors to peritoneum and
the splenic marginal sinus. However, additional studies are necessary to
test this hypothesis.
Plvap may also be an integral mediator of inflammation-induced
migration. It has been previously observed that the blocking of Plvap in
vivo reduced the number of monocytes found in the peritoneum after the
induction of peritonitis (31). Our results show that Plvap has a novel role
in the progression of leukocyte migration to peritoneum not just in
inflammation but also in the steady state. The global deletion or specific
obliteration of Plvap in endothelial cells reduced the migration not just of
B cells but also others leukocytes by approximately 80% in steady state. In
addition, when we restore the expression of Plvap exclusively in
endothelial cells, we observed the rescue of B cells number in steady state,
suggesting that Plvap expression in endothelial cells is the master
regulator of immune cell migration to peritoneum.
c. Plvap−/− vessels leak plasma components leading to hypoproteinemia and
formation of ascites, a condition known to reduce viability of resident
peritoneal macrophages and other immune cell subsets. Deletion of Plvap
may induce conditions depleting the peritoneal progenitors of B-1 and MZ
B cells. Experiments involving Plvap deletion at adult stages should shed
light on which mechanism(s) are involved.
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In conclusion, the expression of the glycoprotein Plvap on endothelial cells is a key
regulator of B cells in the peritoneum, as well as, immature IgM+ B cells in the spleen. It
also has a physiological role in facilitating the production of natural IgM and IgA antibodies
by peritoneal and splenic IgM+ B cells. Collectively, our findings point to a novel
immunologic significance for Plvap in innate humoral immunity. Future work will
determine the precise mechanism by which Plvap regulates B cell subsets in peritoneum and
spleen.
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Plvap Plasmalemma Vesicle Associated Protein
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Figure 1.
IgM+IgDlo B cells are reduced in the Plvap deficient mice. Splenocytes from wild type,
heterozygous or Plvap−/− mice were analyzed for the proportion of different B cells
subpopulation. A) Representative histogram of B220 expression on splenocytes. The
number in the corner represents the percentage of B220+ cells. B) Representative contour
plot of IgD and IgM expression in B220+ B cells. The number in the upper right corner
represents the percentage of IgD+ B220+ cells, whereas the number down in the corner
shows the percentage of IgM+IgD− B220+ B cells. C) Quantification of percentage (top
graph) and absolute number (bottom graph) IgM+IgD− B220+ B cells in spleen from wild
type, heterozygous or Plvap−/− mice. D) Representative contour plot of CD21/35 and IgM
Elgueta et al. Page 16
J Immunol. Author manuscript.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
expression on B220+ B cells. The number in each corner represents the percentage of
different gates which B cells were divided. E) Quantification of CD21/35loIgM+ B cells in
spleen from wild type, heterozygous or Plvap−/− mice. F) Contour plots of CD23 and HSA
expression on CD21/35loIgM+ B cells. G) Quantification of the percentage of T2 and T1
CD21/35loIgM+ B cells. *=p<0.05. n=4 independent experiments with at least 3 Plvap−/−
mice/experiment.
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Figure 2.
B cells are absent in the peritoneum of Plvap−/− mice. A) Quantification of total number of
cells in the peritoneum from wild type or Plvap−/− mice is shown in the graph. B) A
representative contour plot of IgM and IgD expression on peritoneal B cells from wild type,
heterozygous or Plvap−/− mice is shown. The number in each corner represents the
percentage of IgD+/IgMlo (upper corner) and IgD−/IgM+ (lower corner) B cells. C)
Percentage and D) Absolute number of IgD+/IgMlo (left graph) and IgM+/IgD− (right graph)
B cells in peritoneum lavage from wild type, heterozygous or Plvap−/− mice. *=p<0.05,
**=p<0.01. n=4 independent experiments with at least 3 Plvap−/− mice/experiment.
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Figure 3.
Plvap expression on T cells, dendritic cells and B cells. A) Gate on CD4 and CD8 T cells
(Left panel), Plvap expression on CD8 (middle panel) and CD4 T cells (right panel). B)
Plvap expression on dendritic cells (left panel, gated in CD11c) from mice immunized with
(black line) or without (grey line) 50 ug of LPS 12 hrs before. As a control of activation of
dendritic cells, CD80 expression has been shown in the right panel (Black line: immunized
with LPS; grey line: non-treated). C) Plvap expression on B cells from mice immunized with
(right panel) or without (left panel) 50 ug of LPS 12 hrs before. B cells were gated on B220
and CD38 double positive. D) Confocal micrographs of spleen frozen sections labeled with
anti-Plvap (red), anti-B220 (blue) and CD169 (green).
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Figure 4.
Plvap expression on the hematopoietic compartment does not affect the localization of B
cells in the spleen and peritoneum compartment. A and D) A representative contour plot of
IgM and IgD expression on spleen (top panel) and peritoneal (bottom panel) B cells from
CD19CrexPlvapL/L (A) or VavCrexPlvapL/L (D) with correspondingly littermate controls is
shown. The number at the top and bottom in each plot represents the percentage of
IgD+/IgMlo and IgM+/IgD− B cells respectively. B, C, E and F) Quantification of IgD+/
IgMlo (right graph) and IgM+/IgD− (left graph) B cells from spleen (B and E) and
peritoneum lavage (C and F) from CD19 Cre x PlvapL/L (B and C) or Vav Cre x PlvapL/L (E
and F) mice. n=3 independent experiments with at least 3 mice/experiment.
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Figure 5.
Localization of B1 B cells in spleen and peritoneum is reduced in the lack of Plvap
expression on endothelial cells. A) A representative contour plot of IgM and IgD expression
on spleen B cells from Tie2CrexPlvapL/L (right panel) and littermate control mice (PlvapL/L,
left panel) is shown. The number at the top and bottom in each plot represents the
percentage of IgD+/IgMlo and IgM+/IgD− B cells respectively. B) Percentage of IgD+/IgMlo
(left graph) and IgM+/IgD− (right graph) B cells in spleen from Tie2CrexPlvapL/L and
littermate control mice. C) Absolute number of IgD+/IgMlo (left graph) and IgM+/IgD−
(right graph) B cells in spleen from Tie2CrexPlvapL/L and littermate control mice. D) A
representative contour plot of IgM and IgD expression on peritoneal B cells from
Tie2CrexPlvapL/L (right panel) and littermate control mice (left panel) is shown. The number
at the top and bottom in each plot represents the percentage of IgD+/IgMlo and IgM+/IgD− B
cells respectively. E) Percentage of IgD+/IgMlo (left graph) and IgM+/IgD− (right graph) B
cells from peritoneum lavage of Tie2CrexPlvapL/L and littermate control mice. F) Absolute
number of IgD+/IgMlo (left graph) and IgM+/IgD− (right graph) B cells from peritoneum
lavage of Tie2CrexPlvapL/L and littermate control mice. *=p<0.05, **=p<0.01. n=3
independent experiments with at least 3 Plvap−/− mice/experiment.
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Figure 6.
Localization of B1 B cells in spleen and peritoneum is recovered with Plvap expression on
endothelial cells. A and D) A representative contour plot of IgM and IgD expression on
spleen (A) and peritoneal (D) B cells from Plvap ECRC (right panel), Plvap−/− (middle
panel) and wild type (left panel) mice. The number at the top and bottom in each plot
represents the percentage of IgD+/IgMlo and IgM+/IgD− B cells respectively. (B and E)
Percentage of IgD+/IgMlo (left graph) and IgM+/IgD− (right graph) B cells from spleen (B)
and peritoneum lavage (E) of Plvap ECRC (grey bar), Plvap−/− (white bar) and wild type
(black bar) mice. (C and F) Absolute numbers of IgD+/IgMlo (left graph) and IgM+/IgD−
(right graph) B cells from spleen (C) and peritoneum lavage (F) of PlvapECRC (grey bar),
Plvap−/− (white bar) and wild type (black bar) mice. **=p<0.01. n=3 independent
experiments with at least 3 mice/group.
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Figure 7.
Plvap does not affect the development of the B cells. Defect in the number of B cells is not
due to a development issue. A) Percentage of IgM+/IgD− (left graph) and IgD+/IgMlo (right
graph) B cells in spleen from PlvapL/L, PlvapiECKO and PlvapiECRC mice. B) Absolute
number of IgM+/IgD− (left graph) and IgD+/IgMlo (right graph) B cells in spleen from
PlvapL/L, ERTCrexPlvapL/L and ERTCrexPlvapECRC mice. C) Percentage of IgM+/IgD− (left
graph) and IgD+/IgMlo (right graph) B cells from peritoneum lavage of PlvapL/L,
PlvapiECKO and PlvapiECRC mice. D) Absolute number of IgM+/IgD− (left graph) and
IgD+/IgMlo (right graph) B cells from peritoneum lavage of PlvapL/L, PlvapiECKO and
PlvapiECRC mice. E) A representative contour plot of immature (B220+IgMhiIgD+), mature
B cells (B220+IgMintIgD+) and pre-B cell (B220+IgM+IgD+) from bone marrow of
PlvapL/L, PlvapiECKO and PlvapiECRCmice. The number in each plot represents the
percentage of each subset. F) Percentage and G) absolute number of immature, mature and
Elgueta et al. Page 23
J Immunol. Author manuscript.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
pre-B cell from bone marrow of PlvapL/L, PlvapiECKO and PlvapiECRC mice. *=p<0.05,
**=p<0.01. n=2 independent experiments with at least 6 mice/group/experiment.
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